Shots: Pacific to get $8.00/share making $1.2B as total deal value in cash, with its expected closure in Q2’19 The acquisition is a focus to combine Pacific’s Sequel SMRT Technology for expansion of its biological discovery platform by bringing short- and long-read sequencing technologies together Sequel SMRT (Single-Molecule Real-Time) Technology is an automated system with […]Read More
Tags : Pacific Biosciences
Latest Posts
Categories
Related Topics
AbbVie
Acquire
Adults
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Collaborate
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
EU
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Merck
Novartis
P-III
patients
Pfizer
receives
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
the US FDA
Treat
Treatment
US